key: cord-0331877-86zi5lc3
authors: Li, Y.; Fang, X.; Pei, R.; Fan, R.; Chen, S.; Zeng, P.; Ou, Z.; Deng, J.; Zhou, J.; Sun, Z.; Liu, L.; Peng, H.; Chen, X.; Su, Z.; He, J.; Guan, W.; Hu, Z.; Fu, Y.-X.; Zhang, J.
title: Immunogenicity and safety of the homogenous booster shot of a recombinant fusion protein vaccine (V-01) against COVID-19 in healthy adult participants primed with a two-dose regimen
date: 2021-11-08
journal: nan
DOI: 10.1101/2021.11.04.21265780
sha: b6ad3cafb0ed229c1ac2a89b93c01760a774f325
doc_id: 331877
cord_uid: 86zi5lc3

Background: Rising concerns over waning immunity and reduction in neutralizing activity against variants of concern (VOCs) have contributed to deploying booster doses by different strategies to tackle the COVID-19 pandemic. Preliminary findings from Phase I and II have shown that V-01, a recombinant fusion protein vaccine against COVID-19, exhibited favorable safety and immunogenicity profiles in 1060 adult participants of both younger and senior age. Herein, we aimed to assess the immunogenicity and safety for a booster dose in participants previously primed with a two-dose 10mcg V-01 regimen (day 0, 21) from phase I trial, providing reassuring data for necessity and feasibility of a homogenous booster dose. Methods: We conducted a single-arm, open-label trial at the Guangdong Provincial Center for Disease Control and Prevention (Gaozhou, China). Forty-three eligible participants who were previously primed 4-5 months earlier with two-dose 10mcg V-01 regimen from phase I trial received booster vaccination. We primarily assessed the immunogenicity post-booster vaccination, measured by RBD-binding antibodies using ELISA and neutralizing activity against wild-type SARS-CoV-2 and emerging variants of concern (VOCs) using neutralization assays. We secondarily assessed the safety and reactogenicity of the booster vaccination. Results: The third dose of V-01 exhibited significant boosting effects of humoral immune response in participants primed with two-dose 10g V-01 regimen regarding both wild-type SARS-CoV-2 and VOCs. We observed a 60.4-folds increase in neutralizing titres against SARS-CoV-2 of younger adults, with GMTs of 17 (95%CI: 12-23) prior to booster vaccination in comparison to 1017 (95%CI: 732-1413) at day 14 post booster vaccination; and a 53.6-folds increase in that of older adults, with GMTs of 14 (95%CI: 9-20) before booster vaccination in comparison to 729(95%CI: 397-1339) at day 14 post-booster vaccination. The neutralizing titres against SARS-CoV-2 Delta strain also demonstrated a sharp increase from the day of pre booster vaccination to day 14 post booster vaccination, with GMTs of 11 (95%CI:8-15) versus 383 (95%CI:277-531) in younger adults (35.4-folds increase), and 6.5(95%CI: 5-8) versus 300(95%CI:142-631) in older adults (46.0-folds increase), respectively. We also observed a considerable and consistent increase of pseudovirus neutralizing titres against emerging VOCs from day 28 post second vaccination to day 14 post booster vaccination, with GMTs of 206 (95%CI:163-259) versus 607 (95%CI: 478-771) for Alpha strain, 54 (95%CI:38-77) versus 329 (95%CI: 255-425) for Beta strain, 219 (95%CI:157-306) versus 647 (95%CI: 484-865) for Delta strain. Our preliminary findings indicate a homogenous booster dose of V-01 was safe and well-tolerated, with overall adverse reactions being absent or mild-to-moderate in severity, and no grade 3 or worse AEs were related to booster vaccination. Conclusions: A homogenous booster immunization in participants receiving a primary series of two-dose V-01 elicited a substantial humoral immune response against wild-type SARS-CoV-2 and emerging VOCs, along with a favorable safety and reactogenicity profile. Our study provided promising data for a homogenous prime-boost strategy using recombinant protein vaccine to tackle the ongoing pandemic, potentially providing broad protection against emerging VOCs and overcoming waning immunity.

well-tolerated, with overall adverse reactions being absent or mild-to-moderate in severity, and no grade 3 or worse AEs were related to booster vaccination.

Conclusions: A homogenous booster immunization in participants receiving a primary series of two-dose V-01 elicited a substantial humoral immune response against wild-type SARS-CoV-2 and emerging VOCs, along with a favorable safety and reactogenicity profile. Our study provided promising data for a homogenous prime-boost strategy using recombinant protein vaccine to tackle the ongoing pandemic, potentially providing broad protection against emerging VOCs and overcoming waning immunity. ; Recombinant fusion protein vaccine; Immunogenicity; Safety; SARS-CoV-2; VOCs . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Introduction Globally is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 8, 2021. ; https://doi.org/10.1101/2021.11.04.21265780 doi: medRxiv preprint prime-boost immunization (a strategy also called mix-and-match) in Pfizer and AstraZeneca COVID-19 vaccines. The heterologous prime-boost vaccination regimen elicited significantly higher neutralization capacity than homologous ChAdOx1 or BNT162b2 immunization 1 . It is speculated that the mix-and-match strategies may elicit more potent and broader immune responses (including both humoral and cellular immune responses), which can also provide flexible choices to speed up vaccination campaigns worldwide for better control of the current pandemic.

Additionally, as the dominant Delta variant (B.1.617.2), accounting for over 95% of the new SARS-CoV-2 infections, surges worldwide in the last few months, the number of SARS-CoV-2 new infections continues to rise, reversing what had been a decline since early 2021. Notably, real-world evidences have indicated reduced protective efficacy or neutralization activity for vaccines that gained official approval or emergency use authorization (EUA) against COVID-19 2-4 , which might be explained by the latest immune durability data exhibiting a slight expected decline in titres of binding and neutralizing antibodies 5 . These findings are consistent with the estimation of a statistical model that vaccine with an initial efficacy of 95% would expect to maintain efficacy of 77% after 250 days, while an initial efficacy of 70% may drop to a lower efficacy of 33% after 250 days, on the prerequisite that neutralization is the principal mechanism of protection 6 . Particular attention should be paid that even a considerable number of fully vaccinated individuals experienced breakthrough infections [7] [8] [9] . A booster exposure to antigen may awaken memory cells produced in the primary dose regimen, leading to a faster and stronger immune response (a process called affinity maturation for memory B cells). A study has shown that an additional dose of vaccine administered for 6 months or a longer interval after a second dose effectively recalled specific immune responses to SARS-CoV-2, resulting in a remarkable increase in antibody levels 10 . There have been substantial evidences that some SARS-CoV-2 variants acquired resistance to neutralizing antibodies generated by vaccination, reduction by a factor of several to tens of folds [11] [12] [13] . Nevertheless, it is assumed that high titer of neutralizing antibody is still correlated with protection, even in the presence of emerging VOCs that gained higher is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 8, 2021. ; https://doi.org/10.1101/2021.11.04.21265780 doi: medRxiv preprint resistance to neutralization, and protection against severe COVID-19 cases remained preserved [14] [15] [16] [17] . Ultimately, among immuno-compromised and immuno-suppressed populations, fold-reductions in antibody titres were observed after two mRNA vaccine doses [18] [19] [20] [21] Recently, rising concerns over waning immune response and reduction in neutralizing activity against variants of concern (VOC) have contributed to deploying booster shots 23 , including Russian, China, Brazil, the USA, and United Arab Emirates etc. CDC of the United States has announced that vaccine booster shots are available for vaccine recipients (completed their initial series for at least 6 months) aged over 65 years, or at-risk populations, such as living in long-term care settings, having underlying medical conditions, etc. The unequitable access (at-risk population remaining unvaccinated in low-income countries) to safe and effective vaccines across regions, absence of a reliable correlate of protection, inadequate data on performance of booster shots, and other considerations (e.g., optimal timing, boosting strategy and feasibility) might be the primary reasons for the moratorium on boosters by WHO until at least the end of 2021. Currently, evidences for prime-boost vaccination strategy remain sparse, although the reassuring data on the necessity of booster shots are trickling in. V-01, a recombinant fusion protein vaccine against COVID-19, in which RBD is armed with an interferon-α (IFN-α) at the N-terminus and dimerized by human IgG1 Fc at the C-terminus, with further addition of a pan HLA-DR-binding epitope (IFN-PADRE-RBD-Fc dimer), were designed as a strategic self-adjuvanted antigen with the conventional alum adjuvant 24 . Previous studies 25 26 have shown that V-01 exhibited favorable safety profiles and provoked substantial immune responses in 1060 participants aged 18 years and older. An additional dose . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 8, 2021. ; https://doi.org/10.1101/2021.11.04.21265780 doi: medRxiv preprint was inoculated in participants previously (4-5 months earlier) primed with the two-dose regimen of 10 µg V-01 (day 0, 21) in phase Ⅰ trial. Herein, we present the preliminary immunogenicity and safety findings of the booster shot in fully vaccinated cohorts (two-dose 10 µg V-01) in phase Ⅰ.

We initiated a single-arm, open-label trial at the Guangdong Provincial Center for Disease Control and Prevention (Gaozhou, China). Eligible participants were those who completed the initial two-dose regimens of 10μg V-01 in phase I trial 25 4-5 months earlier and who did not meet the withdrawal criteria, voluntarily consented to participate in this trial, agreed to take effective contraceptive measures (women of childbearing potential) during the study, and without a history of SARS-CoV-2 infection or close contact to asymptomatic individuals. Exclusion criteria were: receipt of a COVID-19 vaccine other than V-01; hyperpyrexia (axillary temperature ≥ 39.0°C) lasting ≥3 days following a previous V-01 administration; severe or medically attended allergic reactions following a previous V-01 inoculation; newly diagnosed severe chronic diseases or pre-existing chronic diseases poorly controlled by medication following primary V-01 immunization (for participants ≥60 years of age); any confirmed or suspected immunosuppression or immunodeficiency state as determined by medical history (e.g. HIV, asplenia); recurrent severe infections and use of immunosuppressive drugs, except for topical steroids or short-term oral steroids within the past 6 months; pregnant or lactating females, or those who plan to become pregnant within 6 months after the booster dose; receipt of immunoglobulin and/or any blood products within 3 months prior to booster immunization; and any other conditions that, in the opinion of the investigator, might interfere with the assessment of vaccine safety and immunogenicity outcomes or pose additional risks. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 8, 2021. ; https://doi.org/10.1101/2021.11.04.21265780 doi: medRxiv preprint trial was registered with ClinicalTrials.gov (NCT05050474) and was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki.

Blinding and masking were not applicable in this open-label, single-arm study.

Each eligible participants will be assigned a unique number based on the sequential order of enrollment.

Each participant received an intramuscular (IM) booster injection of 10µg V-01 in participants who were primed 4-5 months earlier with a two-dose regimen of 10µg V-01 from phase Ⅰ trial. Subjects were scheduled for follow-up visits till 6 months after booster vaccination.

On day 0, before the booster inoculation, participants were screened for eligibility by their demographic characteristics, physical examinations, medical history, vital signs (blood pressure, pulse, and temperature), urine pregnancy tests (female of childbearing potential only); and blood samples were collected for baseline immune response evaluation. After the booster injection, participants were monitored for 30min for potential prompt post-vaccination adverse reactions. In the subsequent 7 days following the booster shots, participants were instructed to complete a diary card to record any AEs experienced (solicited local/systemic AEs and unsolicited AEs), daily body temperatures as well as concomitant medications. Solicited local AEs included pain, pruritus, redness, swelling, rash, and induration; solicited systemic AEs included fever, diarrhea, constipation, dysphagia, anorexia, vomiting, nausea, myalgia, arthralgia, headache, cough, dyspnea, pruritus (non-injection site), skin and mucosa abnormity, acute allergic reaction, and fatigue. On day 7, participants returned to the study site for diary card submission and were instructed to document any unsolicited is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 8, 2021. 

A total of 43 participants were recruited in this trial to provide a preliminary assessment of the immunogenicity, safety and reactogenicity of booster shots in primary vaccinated cohorts (two-dose 10μg V-01 regimen). We performed safety analysis in boost Safety Set (bSS), including all participants who received the booster dose. We conducted immunogenicity analysis in boost Per Protocol Set (bPPS), is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 8, 2021. ; https://doi.org/10.1101/2021.11.04.21265780 doi: medRxiv preprint including participants who had completed the booster immunization and had completed pre-and post-immunization blood sampling with available antibody results.

We present counts and percentages of AEs, including overall AEs, AEs related to vaccination, AEs classified as grade 3 or worse, AEs leading to participant's withdrawal. Descriptive summary statistics (counts, percentages) will be provided for any AE. The GMTs with associated Clopper-Pearson 95% CIs for the neutralizing and RBD-binding antibodies against wild-type SARS-CoV-2 were calculated. The GMTs of cross-neutralizing antibodies along with 95% CIs were also calculated for each VOCs after booster immunization. We applied a χ² test or Fisher's exact test to analyze categorical data and a t-test to compare log-transformed antibody titres between groups. Analyses were conducted using SAS 9.4 (SAS Institute Inc., San Diego, CA, USA), then graphed using GraphPad Prism 8.0 (GraphPad Software Inc., San Diego, CA, USA). P value less than 0.05 was considered statistically significant.

In this trial (Fig. 1) A booster dose of V-01 exhibited significant boosting effects in terms of humoral immune response for participants primed with two-dose 10μg V-01 regimen regarding the RBD-binding IgGs against wild-type SARS-CoV-2. Following the booster dose, the RBD-binding antibody titres exhibited a dramatic increase at 14d, 28d post booster immunization compared with pre booster levels ( Fig. 2A and 2B) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Following the booster dose administration, the neutralizing antibody titres against wild-type SARS-CoV-2 exhibited a striking increase (Fig. 3A and 3B Our preliminary safety results indicated that a booster dose of V-01 was safe and well-tolerated, with overall AEs being predominantly absent or mild-to-moderate in severity (Table 1) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 8, 2021. ; https://doi.org/10.1101/2021.11.04.21265780 doi: medRxiv preprint homogenous booster immunization of V-01, with only one case of grade 2 arthralgia reported in the older adult cohorts and none reported in the younger adult group. As regard to unsolicited AEs, 2 cases (2/23, 8.7%) in the younger cohort, 1 case (1/20, 5.0%) in the older cohort were reported within 30d following the booster vaccination, but were all assessed as unrelated to the booster vaccination by the investigator.

The safety and immunogenicity of V-01 have been previously assessed in a randomized, double-blind, placebo-controlled phase I trial using a dose-escalation and age-sequential design with a sentinel strategy, followed by the phase Ⅱ trial with larger population of participants to further evaluate the immunogenicity and safety.

Findings from phase Ⅰ/Ⅱ trial have substantiated a favorable immunogenicity and safety profile of V-01 both in younger adult and geriatric population, and advanced the two-dose, 10µg V-01 regimen to be tested in an international multicenter, large-scale phase Ⅲ efficacy trial 25 26 . In this study, a homogenous booster dose in participants, who were primed 4-5 months earlier with two-dose 10µg V-01, not only elicited a potent boosting effect against both wild type and the dominant Delta SARS-CoV-2 strains but also showed a promising safety profile following V-01 booster.

Our preliminary findings provided reassurance that a homogenous booster shot of V-01 not only reversed the waning immunity to a steep increase in terms of antibody titres against SARS-CoV-2, but also elicited boosting effects against emerging VOCs.

The humoral antibody levels faded gradually over time, judging by the fold-reduction of the antibody titer from day 28 post the second vaccination to the day of before booster vaccination, although RBD-binding antibody and neutralizing antibody in most of the subjects remained positive before booster vaccination. The degree of change for neutralizing antibody titres against live SARS-CoV-2 after the boosting dose as compared to second dose was much more significant than RBD-binding IgGs, indicating that V-01 booster dose could preferentially augment the functionality of neutralizing rather than increase quantity of total antibodies. Remarkably, at day 14 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 8, 2021. ;  following the booster vaccination, neutralizing capacity against wild type and Delta strain of SARS-CoV-2 magnified by a factor of 60. 4 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 8, 2021. ; https://doi.org/10.1101/2021.11.04.21265780 doi: medRxiv preprint

The study has several limitations: (1) the administration interval between the booster dose and the second dose all ranged within 4-5 months, which might need a broader spectrum of range and further stratification for roll-out timing for booster doses. From public health perspective, the optimal timing of booster shot after prime immunization should consider multiple factors, including the current prevalence of COVID-19, supply of COVID-19 vaccine, emerging VOCs epidemiology, etc. (2) cross-neutralizing panels at day 28 after second vaccination who received a two-dose 10µg V-01 regimen in phase Ⅱ was different from the cohorts receiving a booster dose. As a consequence, the comparison of cross-neutralizing activities against variants between primary two-dose series and booster vaccination should be interpreted with caution. (3) the sample size is relatively small, which is insufficient to assess rare vaccine-related AEs. (4) The long-term safety data of current cohorts in phase Ⅰ trial was terminated since the application of the booster shots, and the T-cell immunity has not yet been analyzed.

In conclusion, the booster dose of V-01 in participants previously primed with is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 8, 2021. ; https://doi.org/10.1101/2021.11.04.21265780 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 8, 2021. ; https://doi.org/10.1101/2021.11.04.21265780 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 8, 2021. ; https://doi.org/10.1101/2021.11.04.21265780 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 8, 2021. ; Table 1 Overall adverse events, solicited local and systemic adverse reactions following booster dose of V-01 stratified by age Adver se events/r eactions Younger adults (18-59 years, N=23)

Older adults (≥60 years, N=20) Data are presented as cases of adverse events/total participants in this cohort (%)

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 8, 2021. ; https://doi.org/10.1101/2021.11.04.21265780 doi: medRxiv preprint

Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant -National Healthcare Safety Network

Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults -United States

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

What should define a SARS-CoV-2 "breakthrough" infection?

Breakthrough Infections of SARS-CoV-2 Gamma Variant in Fully Vaccinated Gold Miners

Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

COVID vaccine boosters: the most important questions

Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2

Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial

Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

B cell memory: understanding COVID-19

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

This study is partially supported by the Emergency Key Program of Guangzhou Laboratory, Grant No. EKPG21-21, and funded by LivzonBio Inc. China. We thank all participants who volunteered for this study.

Xujia Chen, Zhipeng Su and Xi Chen are the employees of LivzonBio Inc. China.Other authors declare no competing interest..